Approval · Notice of Compliance 30948 · 2023
NAT-BENDAMUSTINE: Notice of Compliance 30948
Issued May 11, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30948
- Date
- May 11, 2023
- Company
- Natco Pharma (Canada) IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph
- Canadian reference product
- TREANDA (Teva Canada Limited)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NAT-BENDAMUSTINE | Not yet assigned | — |
Medicinal ingredients
- BENDAMUSTINE HYDROCHLORIDE 25 MG per VIAL
- BENDAMUSTINE HYDROCHLORIDE 100 MG per VIAL